European active surveillance of renal cell carcinoma study (E.A.S.E. RCC study) - EASE

CuraTrial SMO & Research0 个研究点目标入组 20 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

暂无简介。

•o Males or females, age >= 18 years.
•o Incidental diagnosis at imaging (ultrasonography, CT, MRI) of a solid renal mass < 4 cm in maximum diameter (pT1a)
•o Histologically confirmed RCC by percutaneous needle biopsy at diagnosis. All RCC subtypes are eligible for the study.
•o Patients unfit for active treatment due to advanced age, or co-morbidity, or refusing active treatment.
•o Signed Informed consent.
•o Preparedness to comply with percutaneous tumor biopsy and a close follow-up protocol.

•o Renal tumors with a non-RCC histology (sarcomas, lymphomas, etc.).
•o Tumor related symptoms at presentation.
•o Patients with known genetic diseases associated with RCC (e.g. Van Hippel Landau).
•o Patients unsuitable for biopsy due to need for concomitant anticoagulation or anti-platelet drug use which cannot be transiently discontinued.
•o Patients unsuitable for biopsy due to tumor location or small tumor size.
•o Patients with concurrent systemic treatment for another cancer.
•o Patients with estimated life expectancy < 1 year.

发起方

CuraTrial SMO & Research